Overview

Description

  • NatureRecombinant
  • SourceEscherichia coli
  • Amino Acid Sequence
    • SpeciesHuman
    • SequenceMAPLGEVGNY FGVQDAVPFG NVPVLPVDSP VLLSDHLGQS EAGGLPRGPA VTDLDHLKGI LRRRQLYCRT GFHLEIFPNG TIQGTRKDHS RFGILEFISI AVGLVSIRGV DSGLYLGMNE KGELYGSEKL TQECVFREQF EENWYNTYSS NLYKHVDTGR RYYVALNKDG TPREGTRTKR HQKFTHFLPR PVDPDKVPEL YKDILSQS

Specifications

Our Abpromise guarantee covers the use of ab50034 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    SDS-PAGE

    Functional Studies

  • Endotoxin level< 0.100 Eu/µg
  • Purity> 95 % SDS-PAGE.

  • FormLyophilised
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

    Preservative: None
    Endotoxin level is less than 0.1 ng per µg (1EU/µg).

    This product is an active protein and may elicit a biological response in vivo, handle with caution.

  • ReconstitutionCentrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.2-0.5 mg/ml. This solution can then be diluted into other aqueous buffers and stored at 4oC for 1 week or -20oC for future use. Repeated freeze thaw cycles will result in some loss of activity.

General Info

  • Alternative names
    • FGF 9
    • FGF-9
    • FGF9
    • FGF9_HUMAN
    • Fibroblast growth factor 9
    • GAF
    • Glia Activating Factor
    • Glia-activating factor
    • HBFG 9
    • HBFG9
    • HBGF-9
    • Heparin-binding growth factor 9
    • MGC119914
    • MGC119915
    • SYNS3
    see all
  • FunctionMay have a role in glial cell growth and differentiation during development, gliosis during repair and regeneration of brain tissue after damage, differentiation and survival of neuronal cells, and growth stimulation of glial tumors.
  • Tissue specificityGlial cells.
  • Involvement in diseaseDefects in FGF9 are the cause of multiple synostoses syndrome type 3 (SYNS3) [MIM:612961]. Multiple synostoses syndrome is an autosomal dominant condition characterized by progressive joint fusions of the fingers, wrists, ankles and cervical spine, characteristic facies and progressive conductive deafness.
  • Sequence similaritiesBelongs to the heparin-binding growth factors family.
  • Post-translational
    modifications
    Three molecular species were found (30 kDa, 29 kDa and 25 kDa), cleaved at Leu-4, Val-13 and Ser-34 respectively. The smaller ones might be products of proteolytic digestion. Furthermore, there may be a functional signal sequence in the 30 kDa species which is uncleavable in the secretion step.
    N-glycosylated.
  • Cellular localizationSecreted.
  • Information by UniProt

References for Recombinant human FGF9 protein (ab50034)

ab50034 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab50034.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"